retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Phase 3 Results: 28.7%
Pay in 4 interest-free payments of $5.70 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12


01053-X/asset/68ad1d8b-bb7e-4ca0-8f89-99384d885ca3/main.assets/gr2.jpg)


















